Clinical trials: Crohn Disease in Remission
Inflammatory Bowel Diseases
Correlation Between RISANKIZUMAB's Trough Levels, Clinical and Biological Remission in Moderate to Severe Crohn's Disease: a Retrospective Multicentric Study
The goal of this observational study is to determine if, as with other therapeutics such as anti-TNF, trough levels of Risankizumab are correlated with clinical and biological remission in patients with moderate to severe Crohn's…
- Trial name
- RISE-CD (NCT06589895)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Crohn's Disease
Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease
The purpose of this study is to evaluate effectiveness of 2 months antibiotic course of Azithromycin combined with Metronidazole compared with 2 months antibiotic course of Metronidazole alone.
- Trial name
- NCT01596894
- Testing
- Azithromycin + Metronidazole, Metronidazole
- Where
- Israel
- Volunteers
- 73 people
- Sponsor
- Prof. Arie Levine
Crohn Disease (CD), Ulcerative Colitis (UC)
Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context
Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.
- Trial name
- LEADER (NCT07621783)
- Testing
- Leucine-rich α2-glycoprotein
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Imelda GI Clinical Research Center
Crohn Disease, Crohn Colitis
A Pilot Study to Explore the Role of Gut Flora in Crohn's Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Crohn's disease.
- Conditions
- Crohn Disease, Crohn Colitis, Crohn's Ileocolitis, Crohn Ileitis
- Trial name
- NCT04100005
- Testing
- No intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Crohn's Disease
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease
The goal of this observational study is to learn about the effectiveness and safety of IL-23 inhibitors in adults with active Crohn's disease in real-world clinical practice.
- Trial name
- NCT07545317
- Testing
- IL-23 inhibitor, TNF inhibitors
- Where
- China
- Volunteers
- 665 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Crohn Disease, Remission
Stopping Aminosalicylate Therapy in Inactive Crohn's Disease
The purpose of this study is to assess whether withdrawal of aminosalicylate (5-ASA) is non-inferior to continuation of 5-ASA therapy in Crohn's disease (CD) subjects in remission.
- Trial name
- STATIC (NCT03261206)
- Testing
- 5-ASA Withdrawal
- Where
- 46 sites in Canada, Italy and 2 more
- Volunteers
- 334 people
- Sponsor
- Alimentiv Inc.
Crohns Disease
Vitamin D Treatment for Crohn´s Disease
The purpose of this study is to examine whether vitamin D treatment is effective in Crohn's disease.
- Trial name
- NCT00132184
- Testing
- Vitamin D
- Where
- 4 sites in Denmark
- Volunteers
- 110 people
- Sponsor
- University of Aarhus
Crohn Disease in Remission
Exclusive Enteral Nutrition for Remissionof Crohn's Diseases After Surgery
For patients with Crohn's diseases undergoing surgery，whether postoperative exclusive enteral nutrition(EEN) could delay the endoscopic relapse needs exploration.The trial will investigate the efficacy of postoperative EEN for…
- Trial name
- NCT05214430
- Testing
- 3 months exclusive enteral nutrition after surgery
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Jinling Hospital, China
Crohn's Disease
Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).
A 26 week maintenance study of CDP870 in Crohn's disease
- Trial name
- NCT00152425
- Testing
- Certolizumab Pegol (CDP870)
- Volunteers
- 392 people
- Sponsor
- UCB Pharma
Crohn Disease in Remission
Stratifying Crohn's Using Biomarker Assessment
Crohn's disease (CD) is a relapsing-remitting condition that requires lifelong monitoring. Non-invasive tests such as faecal calprotectin (FC) are more acceptable to patients and cost-effective than invasive tests such as…
- Trial name
- SCUBA (NCT04321863)
- Testing
- Faecal calprotectin (FC), quantitative Faecal Immunochemical Testing (qFIT), Serum and faecal zinc
- Where
- United Kingdom
- Volunteers
- 315 people
- Sponsor
- NHS Greater Glasgow and Clyde
Crohn's Disease
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
The current multicentre phase III study is proposed to confirm in an add-on therapy design compared to a placebo-control group, the efficacy of adipose-derived stem cells (eASCs) from healthy donors for the treatment of complex…
- Trial name
- ADMIRE-CD (NCT01541579)
- Testing
- Cx601, Saline solution
- Where
- 52 sites in Austria, Belgium and 6 more
- Volunteers
- 278 people
- Sponsor
- Tigenix S.A.U.
Crohn Disease
QBECO SSI for Clinical and Endoscopic Remission in Moderate to Severe Crohn's Disease
The QBECO-CD-02 trial in subjects with moderate to severe Crohn's disease (CD) is intended to build on past experience with QBECO SSI and further establish the safety and efficacy of QBECO SSI for the induction of clinical and/or…
- Trial name
- NCT03472690
- Testing
- QBECO-SSI
- Where
- 3 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Qu Biologics Inc.
Crohn's Disease
Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
The purpose of this study is to evaluate the safety of adalimumab for treatment of patients with moderate to severe Crohn's Disease (CD) and to measure the effects of treatment on patient general well-being, health-related…
- Trial name
- NCT00409617
- Testing
- adalimumab
- Where
- 189 sites in Austria, Belgium and 15 more
- Volunteers
- 945 people
- Sponsor
- Abbott
Adolescent, Child
Comparison of Partial and Exclusive Enteral Nutrition in the Treatment of Active Childhood-onset Crohn's Disease
The primary objective of this study is to determine the efficacy of a novel enteral nutrition (EN) protocol (delivering 75% of patient's caloric needs through EN) for induction of remission in patients with active childhood-onset…
- Conditions
- Adolescent, Child, Diet, Crohn Disease
- Trial name
- NCT03176875
- Testing
- ALICALM (75% of daily caloric requirements), ALICALM (100% of daily caloric requirements)
- Where
- Slovenia
- Volunteers
- 50 people
- Sponsor
- University Medical Centre Ljubljana
IBD - Inflammatory Bowel Disease
Long-term Remission After Ileorectal Anastomosis in Crohn's Disease.
Single-center, retrospective, observational study. The medical records of patients who underwent colectomy and ileorectal anastomosis (IRA) for refractory Crohn's colitis between 1996 and 2016 were reviewed.
- Trial name
- NCT06777043
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Inflammatory Bowel Disease
Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose
Healthy Normal Single Ascending Dose and Crohn's patient Multiple Ascending Dose
- Trial name
- NCT00868660
- Testing
- ZP1848
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Zealand Pharma
Inflammatory Bowel Diseases, Remission
Assessing the Effectiveness of a Stress Reduction Intervention in Inflammatory Bowel Disease (IBD)
The investigators have designed a guided, online, tri-component, stress reduction intervention for participants with inflammatory bowel diseases.
- Conditions
- Inflammatory Bowel Diseases, Remission, Perceived Stress
- Trial name
- NCT03831750
- Testing
- Stress Reduction Intervention
- Where
- Canada
- Volunteers
- 101 people
- Sponsor
- University of Alberta
Crohn's Disease
Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease
This study aims to determine which of 3 doses of a non-absorbable antibiotic Rifaximin is most effective in treating active moderate Crohn's disease.
- Trial name
- NCT00528073
- Testing
- Rifaximin-EIR
- Where
- 57 sites in France, Germany and 5 more
- Volunteers
- 410 people
- Sponsor
- Alfasigma S.p.A.
Crohn's Disease
The Vitamin D in Pediatric Crohn's Disease
The purpose of this study is to determine if vitamin D as an adjuvant therapy can improve the outcome (i.e. fewer relapses) and the quality of life, including levels of physical activity, in children with newly diagnosed Crohn's…
- Trial name
- ViDiPeC (NCT02186275)
- Testing
- Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day, Vitamin D3 800 UI/day then 800 UI/day
- Where
- 10 sites in Canada
- Volunteers
- 25 people
- Sponsor
- St. Justine's Hospital
Crohn Disease, Nutrient; Excess
Exclusive Enteral Nutrition in Patients With Ileocaecal Crohn's Disease
Inflammatory bowel diseases are chronic and progressive entities, triggered by exposure to environmental factors in individuals with a genetic background.
- Conditions
- Crohn Disease, Nutrient; Excess, Remission/Regression
- Trial name
- NCT04921033
- Testing
- EEN (Nestle Modulen®), Standart of care
- Where
- Turkey (Türkiye)
- Volunteers
- 256 people
- Sponsor
- Duzce University